Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

By Youn H. Kim, Howard L Liu, S. Mraz-Gernhard, A. Varghese, R. Hoppe. Archives of Dermatology, 2003

685 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. (2010, background): “Long-term follow-up studies of MF/SS are limited,(3-8) with the largest study consisting of 525 patients(8) and only two studies reporting actuarial survival data.(6,8) These studies”
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. (2007, background): “Patient prognosis is based on disease stage.(6) Curative modalities for MF/SS remain elusive and patients with advanced (stage IIB or higher) disease usually develop progressive disease (PD)(6) after becoming intolerant of, or refractory to, multiple treatments.”
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (2013, background): “Moreover, a viable ITK inhibitor would be a promising therapeutic advancement for many T-cell malignancies that are currently difficult to manage.(12,13) Although multiple chemical analogs have been reported,”